Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination

Hervé, Pierre‐Louis; Dhelft, Véronique; Plaquet, Camille; Rousseaux, Anaïs; Bouzereau, Adeline; Gaulme, Laetitia; Tilleul, Sylvain; Ligouis, Mélanie; Donne, Nathalie; Lambert, Paul‐Henri; Hong-Thai, Pham; Wijagkanalan, Wassana; Sampson, Hugh A.; Mondoulet, Lucie

doi:10.1016/j.jconrel.2019.02.004

Cited by 19 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous data generated in murine and porcine models demonstrated that epicutaneous patches can also be used as a vaccine delivery platform, which is especially efficacious at boosting specific pre-existing immunity (24)(25)(26). However, several studies have highlighted the fact that pre-existing immunity, especially antibodies directed against a specific antigen, may interfere with the induction of immune response to an homologous antigen administered as a vaccine (27)(28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

et al. 2021

Self Cite

View full text Add to dashboard Cite

Due to its richness in antigen presenting cells, e.g., dendritic cells (DC), the skin has been identified as a promising route for immunotherapy and vaccination. Several years ago, a skin delivery system was developed based on epicutaneous patches allowing the administration of antigen through intact skin. Using mouse models, we have shown that epicutaneous allergen application leads to a rapid uptake and transport of allergen-positive cells to skin-draining lymph nodes (LN). This occurred primarily in animals previously sensitized to the same allergen. In that context, we sought to better understand the role of the specific preexisting immunity in allergen capture by skin DC and their subsequent migration to LN. Specifically, we investigated the role of humoral immunity induced by sensitization and the involvement of IgG Fc receptors (FcγR). Epicutaneous patches containing fluorescently-labeled ovalbumin (OVA) were applied to naïve mice that had previously received either sera or purified IgG isolated from OVA-sensitized mice. To investigate the involvement of FcγR, animals received 2.4G2 (anti-FcγRII/RIII) blocking antibody, 24 hours before patch application. Mice that received sera or purified IgG originating from OVA-sensitized mice showed an increase in the quantity of OVA-positive DC in skin and LN. Moreover, the blockade of FcγR reduced the number of OVA-positive DC in LN to a level similar to that observed in naïve animals. Overall, these results demonstrate that preexisting specific-IgG antibodies are involved in allergen capture by skin DC following EPIT through the involvement of antigen-specific IgG-FcγR.

show abstract

Section: Discussionmentioning

confidence: 99%

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…It enables the disruption of the stratum corneum in a highly controlled and adjustable fashion, simultaneously providing an intrinsic adjuvanting effect. Consequently, this technology has been intensively investigated for the pain-free prophylactic and therapeutic treatment of type I allergies and tumours [92,98,99]. Despite a two-step administration process (microporation followed by antigen application), laser ablation could potentially be valuable in mass vaccination campaigns, particularly in combination with dry vaccine patches, offering advantages such as heat stability, the avoidance of needle-related injuries, and improved uptake, at a cost similar to conventional vaccination [99].…”

Section: Cutaneous Immunisationmentioning

confidence: 99%

“…Currently, the major challenge is how to standardise the pore depth and ensure sufficient reproducibility, due to the variability of skin thickness depending on body site, age and ethnicity [92]. The available results encourage further investigations in healthy adults to evaluate the safety and efficacy of laser microporation prior to, for example, vaccine patch application [98].…”

Section: Cutaneous Immunisationmentioning

confidence: 99%

Technological Approaches for Improving Vaccination Compliance and Coverage

et al. 2020

View full text Add to dashboard Cite

Vaccination has been well recognised as a critically important tool in preventing infectious disease, yet incomplete immunisation coverage remains a major obstacle to achieving disease control and eradication. As medical products for global access, vaccines need to be safe, effective and inexpensive. In line with these goals, continuous improvements of vaccine delivery strategies are necessary to achieve the full potential of immunisation. Novel technologies related to vaccine delivery and route of administration, use of advanced adjuvants and controlled antigen release (single-dose immunisation) approaches are expected to contribute to improved coverage and patient compliance. This review discusses the application of micro- and nano-technologies in the alternative routes of vaccine administration (mucosal and cutaneous vaccination), oral vaccine delivery as well as vaccine encapsulation with the aim of controlled antigen release for single-dose vaccination.

show abstract

“…The group used the P.L.E.A.S.E. system to create laser‐induced epidermis‐limited perforation to augment the efficacy of epicutaneous vaccination using a noninvasive and needle‐free skin patch Viaskin which has been successfully used for transcutaneous delivery of food allergen for immunotherapy and genetically inactivated recombinant pertussis toxin and respiratory syncytial virus (RSV) N‐nanorings for vaccination. This approach induced limited skin inflammation with upregulation of IL‐1β and IL‐33, enhanced Langerhans cell activation and facilitated migration of antigen‐positive DCs in skin to draining lymph nodes, ultimately inducing a rapid increase in antibody titers against a model vaccine and recombinant pertussis toxin.…”

Section: Ablative Fractional Laser Adjuvantmentioning

confidence: 99%

Laser adjuvant for vaccination

Kashiwagi

2020

FASEB j.

View full text Add to dashboard Cite

The use of an immunologic adjuvant to augment the immune response is essential for modern vaccines which are relatively ineffective on their own. In the past decade, researchers have been consistently reporting that skin treatment with a physical parameter, namely laser light, augments the immune response to vaccine and functions as an immunologic adjuvant. This “laser adjuvant” has numerous advantages over the conventional chemical or biological agents; it is free from cold chain storage, hypodermic needles, biohazardous sharp waste, irreversible formulation with vaccine antigen, undesirable biodistribution in vital organs, or unknown long‐term toxicity. Since vaccine formulations are given to healthy populations, these characteristics render the “laser adjuvant” significant advantages for clinical use and open a new developmental path for a safe and effective vaccine. In addition, laser technology has been used in the clinic for more than three decades and is therefore technically matured and has been proved to be safe. Currently, four classes of laser adjuvant have been reported; ultrashort pulsed, non‐pulsed, non‐ablative fractional, and ablative fractional lasers. Since each class of the laser adjuvant shows a distinct mechanism of action, a proper choice is necessary to craft an effective vaccine formulation toward a desired clinical benefit for a clinical vaccine to maximize protection. In addition, data also suggest that further improvement in the efficacy is possible when a laser adjuvant is combined with chemical or biological adjuvant(s). To realize these goals, further efforts to uncover the molecular mechanisms of action of the laser adjuvants is warranted. This review provides a summary and comments of the recent updates in the laser adjuvant technology.

show abstract

Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination

Cited by 19 publications

References 45 publications

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

Technological Approaches for Improving Vaccination Compliance and Coverage

Laser adjuvant for vaccination

Contact Info

Product

Resources

About